Trending Alert: These 6 Companies Are Trending Now

Tickers Inside Powered by [FinancialMarketMovers.com]( Good Morning! Below is a list of 6 stocks that are trending with positive investor sentiment, news headlines, and buy ratings from top Wall Street analysts. Our editors are keeping an eye on these stocks and adding them to our watchlist to see if the momentum continues. --------------------------------------------------------------- Sponsor [New EV Lithium Player?]( company surges over 178% after recent acquisition in new Lithium epicenter! [See Report]( --------------------------------------------------------------- [Johnson Controls, JCI]( Summary: Johnson Controls International is a diversified technology company and a multi industrial leader. The company's operations include creation of intelligent buildings, providing efficient energy solutions, integrated infrastructure that work seamlessly together to deliver on the promise of smart cities and communities. Johnson Controls provides building systems, including HVAC (heating, ventilation and air conditioning) controls and security and safety products. Gautam Khanna analyst at TD Cowen reiterated coverage on [Johnson Controls (JCI)](in the Industrials sector with a Buy rating and has set a price target of n/a. Our data shows [Johnson Controls]( currently has 4 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target of $64.75. In addition, TradingView issued a Sell rating for [JCI]( over the next month, Barchart.com has a sell rating and Yahoo! Finance has a Bearish short-term outlook. [For the complete breakdown on JCI, please click here >>]( [Pfizer, PFE]( Summary: Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.'The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines. Trung Huynh analyst at UBS reiterated coverage on [Pfizer (PFE)](in the Healthcare sector with a Hold rating and has set a price target of $27. Our data shows [Pfizer]( currently has 4 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target of $34.25. In addition, TradingView issued a Sell rating for [PFE]( over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bullish short-term outlook. [For the complete breakdown on PFE, please click here >>]( --------------------------------------------------------------- Sponsor [Tiny Lithium Stock Surge!]( t miss out on this tiny stock poised to surge in a massive $183B market opportunity! [Get the Free Report]( --------------------------------------------------------------- [Costco, COST]( Summary: Costco Wholesale Corporation sells high volumes of foods and general merchandise at discounted prices through membership warehouses. The company also operates e-commerce websites in the United States, Canada, the United Kingdom, Mexico, Korea, Taiwan, Japan and Australia. The company's warehouses offer an array of low-priced nationally branded and select private labeled products in a wide range of merchandise categories. Costco offers three types of memberships to its customers: Business, Gold Star, and Executive. Costco generates revenue from two sources: 1) Store sales and 2) Membership fees. Costco offers myriad varieties of food products as well as a vast range of household and lifestyle products, stationeries and appliances. The company also sells gasoline to customers at cheap prices and offers merchandise in the following categories: Food and Sundries, Hardlines, Fresh Foods, Softlines, Ancillary. Dean Rosenblum analyst at Bernstein reiterated coverage on [Costco (COST)](in the Consumer Cyclical sector with a Buy rating and has set a price target of $670. Our data shows [Costco]( currently has 5 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target of $660.80. In addition, TradingView issued a Strong Buy rating for [COST]( over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bearish short-term outlook. [For the complete breakdown on COST, please click here >>]( [ACADIA Pharmaceuticals, ACAD]( Summary: Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on developing innovative medicines to address the unmet medical needs in central nervous system (CNS) disorders. The company's sole marketed drug Nuplazid (pimavanserin) is the first and the only FDA-approved treatment for hallucinations and delusions associated with Parkinson's disease psychosis. The company suffered a setback when the FDA issued a complete response letter to the supplemental new drug application for Nuplazid for treating dementia-related psychosis. Acadia resubmitted the supplemental new drug application to the FDA for pimavanserin for the treatment of hallucinations and delusions associated with Alzheimer's disease psychosis. Notably, several additional studies on Nuplazid n targeting different CNS indications, such as'dementia-related psychosis, schizophrenia inadequate response, schizophrenia negative symptoms and as an adjunctive treatment of major depressive disorder (MDD) are currently underway. Tazeen Ahmad analyst at Bank of America Securities reiterated coverage on [ACADIA Pharmaceuticals (ACAD)](in the Healthcare sector with a Hold rating and has set a price target of $33. Our data shows [ACADIA Pharmaceuticals]( currently has 4 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target of $35.00. In addition, TradingView issued a Buy rating for [ACAD]( over the next month, Barchart.com has a Weak buy rating and Yahoo! Finance has a Bullish short-term outlook. [For the complete breakdown on ACAD, please click here >>]( --------------------------------------------------------------- Sponsor [Prepare for the Next Wave of AI Stocks]( Almost every investor has heard of Nvidia. The AI chipmaker became the 7th trillion-dollar company in history. It’s up 233% this year alone …...9,624% over the last decade. Here’s the exciting thing about investing in AI: [Nvidia was just the beginning.]( Over the next few months, I expect a new wave of AI stocks to take the lead. Some could soar even higher than Nvidia. [Click here to find out which three AI stocks I think have the most potential.]( --------------------------------------------------------------- [Exelixis, EXEL]( Summary: Exelixis, Inc. is an oncology-focused biotechnology company, which primarily focuses on the discovery, development and commercialization of new drugs for the treatment of difficult-to-treat cancers. The company has four approved drugs in its portfolio. Of these, two are derived from cabozantinib, the company's flagship molecule, which is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET. David Lebovitz analyst at Citi reiterated coverage on [Exelixis (EXEL)](in the Healthcare sector with a Buy rating and has set a price target of $31. Our data shows [Exelixis]( currently has 5 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target of $27.60. In addition, TradingView issued a Buy rating for [EXEL]( over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bearish short-term outlook. [For the complete breakdown on EXEL, please click here >>]( [Prologis, PLD]( Summary: Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. Prologis leases modern logistics facilities to a diverse base of customers principally across two major categories: business-to-business and retail/online fulfillment. Camille Bonnel analyst at Bank of America Securities reiterated coverage on [Prologis (PLD)](in the Real Estate sector with a Buy rating and has set a price target of $148. Our data shows [Prologis]( currently has 5 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target of $143.40. In addition, TradingView issued a Buy rating for [PLD]( over the next month, Barchart.com has a Weak buy rating and Yahoo! Finance has a Neutral short-term outlook. [For the complete breakdown on PLD, please click here >>]( --------------------------------------------------------------- Sponsor [AI "wealth window" will close January 9, 2024?]( Next-generation AI technology will create the first $100 TRILLION industry. AI 2.0 will open a brief “wealth window”… That will slam shut January 9, 2024. [>>HERE is everything you need now]( --------------------------------------------------------------- Remember, securities are volatile, so please do your own research. One resource you need to consider using [Tipranks.com]( where as a premium member you get access to all buy ratings, price targets and insider trading signals. [Get more from TipRanks.com here >>]( Thanks for reading! The Editor, [FinancialMarketMovers.com]( --------------------------------------------------------------- Sponsor [The New Epicenter for Lithium!]( company makes big acquisition in new epicenter of Lithium supply for EV's! [Get Symbol]( --------------------------------------------------------------- [To Cancel Your Free Subscription, click here.]( FinancialMarketMovers.com Disclaimer This newsletter contains advertisements which are neither an offer nor recommendation to buy or sell any security. Content marked as "Ad," "Special" or "Sponsor" may be a third party advertisements where the advertiser is paying per click, per lead or per sale and are not endorsed or warranted by our staff or company. Sandpiper Marketing Group, LLC is also being compensated by Summit Publishing Group and Investing Trends up to three dollars per click and may exceed twelve thousand, five hundred dollars per week for placement of specific advertisements contained in this newsletter. Sandpiper Marketing Group, LLC and its principles do not own any of the stocks mentioned in this email or in the article that this email links to. Please see the disclaimer on the advertiser's website for additional information, including their relationship with any mentioned security. Compensation for advertising constitutes a conflict of interest as to our ability to remain objective in our communication regarding any companies profiled. Because of this conflict, individuals are strongly encouraged to not use this newsletter as the basis for any investment decision. This newsletter may contain information regarding investment ideas and third-party ratings regarding specific securities. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. Sandpiper Marketing Group, LLC nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from Sandpiper Marketing Group, LLC to buy or sell any security. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. The content in this newsletter or email is not provided to any individual with a view toward their individual circumstances. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. By opening this email or clicking any links contained, you are reconfirming your opt-in status. You can unsubscribe at any time by clicking the link below in the footer. [If you are not a human, click here.]( This is part of your free subscription to FinancialMarketMovers. FinancialMarketMovers.com part of Sandpiper Marketing Group, LLC | 1519 Mecklenburg Hwy Unit 407 | Mt. Mourne | North Carolina | 28123